{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:01Z","timestamp":1791389161306,"version":"4.3.3"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.<\/jats:p>","DOI":"10.1038\/s41541-025-01366-9","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:46:22Z","timestamp":1770021982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine"],"prefix":"10.1038","volume":"11","author":[{"given":"Ian","family":"Escudero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Gniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhardt","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1366_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1139\/cjm-2020-0572","volume":"67","author":"SK Roy","year":"2021","unstructured":"Roy, S. K. & Bhattacharjee, S. Dengue virus: epidemiology, biology, and disease aetiology. Can. J. Microbiol. 67, 687\u2013702 (2021).","journal-title":"Can. J. Microbiol."},{"key":"1366_CR2","unstructured":"World Health Organization. Dengue Guidelines for Diagnosis, Treatment, Prevention and Control (Accessed 21 November 2023) who.int\/publications\/i\/item\/9789241547871 (2009)."},{"key":"1366_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507 (2013).","journal-title":"Nature"},{"key":"1366_CR4","unstructured":"World Health Organization. Dengue and Severe Dengue (Accessed 7 January 2026) www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue (2023)."},{"key":"1366_CR5","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro2460","volume":"8","author":"MG Guzman","year":"2010","unstructured":"Guzman, M. G. et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8, S7\u2013S16 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"1366_CR6","doi-asserted-by":"publisher","first-page":"100712","DOI":"10.1016\/j.eclinm.2020.100712","volume":"32","author":"Z Zeng","year":"2021","unstructured":"Zeng, Z., Zhan, J., Chen, L., Chen, H. & Cheng, S. Global, regional, and national dengue burden from 1990 to 2017: a systematic analysis based on the Global Burden of Disease Study 2017. eClinicalMedicine 32, 100712 (2021).","journal-title":"eClinicalMedicine"},{"key":"1366_CR7","unstructured":"Africa Health Organisation. Dengue and Severe Dengue Fact Sheet (Accessed 7 January 2026) https:\/\/aho.org\/fact-sheets\/dengue-and-severe-dengue-fact-sheet\/ (2023)."},{"key":"1366_CR8","unstructured":"World Health Organization. Dengue vaccine: WHO position paper \u2013 September 2018. Wkly. Epidemiol. Rec. 93, 457\u2013476 (2018)."},{"key":"1366_CR9","unstructured":"World Health Organization. Dengue - Global Situation (Accessed 7 January 2026) https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON518 (2024)."},{"key":"1366_CR10","unstructured":"World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. Revised and Expanded Edition. https:\/\/iris.who.int\/bitstream\/handle\/10665\/204894\/B4751.pdf?sequence=1&isAllowed=y (2011)."},{"key":"1366_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(02)09964-6","volume":"360","author":"S Hales","year":"2002","unstructured":"Hales, S., de Wet, N., Maindonald, J. & Woodward, A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet 360, 830\u2013834 (2002).","journal-title":"Lancet"},{"key":"1366_CR12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","volume":"4","author":"JP Messina","year":"2019","unstructured":"Messina, J. P. et al. The current and future global distribution and population at risk of dengue. Nat. Microbiol. 4, 1508\u20131515 (2019).","journal-title":"Nat. Microbiol."},{"key":"1366_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/MS9.0000000000000418","volume":"85","author":"S Tabassum","year":"2023","unstructured":"Tabassum, S. et al. Year-round dengue fever in Pakistan, highlighting the surge amidst ongoing flood havoc and the COVID-19 pandemic: a comprehensive review. Ann. Med. Surg. 85, 908\u2013912 (2023).","journal-title":"Ann. Med. Surg."},{"key":"1366_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4269\/ajtmh.2012.11-0770","volume":"87","author":"O Brathwaite Dick","year":"2012","unstructured":"Brathwaite Dick, O. et al. The history of dengue outbreaks in the Americas. Am. J. Trop. Med. Hyg. 87, 584\u2013593 (2012).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR15","doi-asserted-by":"crossref","unstructured":"Warner, J. C. et al. Infections in travellers returning to the UK: a retrospective analysis (2015-2020). J. Travel Med. 30, taad003 (2023).","DOI":"10.1093\/jtm\/taad003"},{"key":"1366_CR16","doi-asserted-by":"publisher","first-page":"taae089","DOI":"10.1093\/jtm\/taae089","volume":"31","author":"A Duvignaud","year":"2024","unstructured":"Duvignaud, A. et al. Epidemiology of travel-associated dengue from 2007 to 2022: a GeoSentinel analysis. J. Travel Med. 31, taae089 (2024).","journal-title":"J. Travel Med."},{"key":"1366_CR17","doi-asserted-by":"publisher","first-page":"taae081","DOI":"10.1093\/jtm\/taae081","volume":"31","author":"LE Wee","year":"2024","unstructured":"Wee, L. E. et al. Dengue versus COVID-19: comparing the incidence of cardiovascular, neuropsychiatric and autoimmune complications. J. Travel Med. 31, taae081 (2024).","journal-title":"J. Travel Med."},{"key":"1366_CR18","unstructured":"World Health Organization. Ten Threats to Global Health in 2019 (Accessed 7 January 2026) https:\/\/www.who.int\/vietnam\/news\/feature-stories\/detail\/ten-threats-to-global-health-in-2019 (2019)."},{"key":"1366_CR19","unstructured":"Public Health Agency. Immunisation\/vaccine Preventable Diseases (Accessed 21 November 2023) https:\/\/www.publichealth.hscni.net\/directorate-public-health\/health-protection\/immunisationvaccine-preventable-diseases#:~:text=After%20clean%20water%2C%20vaccination%20is,Northern%20Ireland%20over%20recent%20years. (2022)."},{"key":"1366_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","volume":"15","author":"SJ Thomas","year":"2019","unstructured":"Thomas, S. J. & Yoon, I. K. A review of Dengvaxia\u00ae: development to deployment. Hum. Vaccin. Immunother. 15, 2295\u20132314 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1366_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00658-2","volume":"8","author":"SJ Thomas","year":"2023","unstructured":"Thomas, S. J. Is new dengue vaccine efficacy data a relief or cause for concern? NPJ Vaccines 8, 55 (2023).","journal-title":"NPJ Vaccines"},{"key":"1366_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1473-3099(17)30752-1","volume":"18","author":"M Aguiar","year":"2018","unstructured":"Aguiar, M. & Stollenwerk, N. Dengvaxia: age as surrogate for serostatus. Lancet Infect. Dis. 18, 245 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1366_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1366_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7006a1","volume":"70","author":"G Paz-Bailey","year":"2021","unstructured":"Paz-Bailey, G. et al. Dengue vaccine: recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm. Rep. 70, 1\u201316 (2021).","journal-title":"MMWR Recomm. Rep."},{"key":"1366_CR25","unstructured":"European Medicines Agency. Qdenga (2023) Summary of Product Characteristics (Accessed 7 January 2026) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qdenga-epar-product-information_en.pdf (2023)."},{"key":"1366_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/v15040860","volume":"15","author":"SK Dutta","year":"2023","unstructured":"Dutta, S. K. & Langenburg, T. A perspective on current flavivirus vaccine development: a brief review. Viruses 15, 860 (2023).","journal-title":"Viruses"},{"key":"1366_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1366_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.4269\/ajtmh.1969.18.954","volume":"18","author":"S Nimmannitya","year":"1969","unstructured":"Nimmannitya, S., Halstead, S. B., Cohen, S. N. & Margiotta, M. R. Dengue and Chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever. Am. J. Trop. Med. Hyg. 18, 954\u2013971 (1969).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","volume":"69","author":"SB Halstead","year":"2003","unstructured":"Halstead, S. B. & Marchette, N. J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am. J. Trop. Med. Hyg. 69, 5\u201311 (2003).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"Suppl 2","key":"1366_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0264-410X(00)00040-2","volume":"18","author":"N Bhamarapravati","year":"2000","unstructured":"Bhamarapravati, N. & Sutee, Y. Live attenuated tetravalent dengue vaccine. Vaccine 18 (Suppl 2), 44\u201347 (2000).","journal-title":"Vaccine"},{"key":"1366_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","volume":"14","author":"DW Vaughn","year":"1996","unstructured":"Vaughn, D. W. et al. Testing of a dengue 2 live-attenuated vaccine (Strain 16681 PDK 53) in ten American volunteers. Vaccine 14, 329\u2013336 (1996).","journal-title":"Vaccine"},{"key":"1366_CR32","first-page":"189","volume":"65","author":"N Bhamarapravati","year":"1987","unstructured":"Bhamarapravati, N., Yoksan, S., Chayaniyayothin, T., Angsubphakorn, S. & Bunyaratvej, A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. World Health Organ. 65, 189\u2013195 (1987).","journal-title":"Bull. World Health Organ."},{"key":"1366_CR33","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","volume":"19","author":"N Kanesa-thasan","year":"2001","unstructured":"Kanesa-thasan, N. et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179\u20133188 (2001).","journal-title":"Vaccine"},{"key":"1366_CR34","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","volume":"29","author":"JE Osorio","year":"2011","unstructured":"Osorio, J. E., Huang, C. Y., Kinney, R. M. & Stinchcomb, D. T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29, 7251\u20137260 (2011).","journal-title":"Vaccine"},{"key":"1366_CR35","first-page":"20","volume":"48","author":"S Yoksan","year":"2017","unstructured":"Yoksan, S. A short history of dengue and Mahidol dengue vaccine. Southeast Asian J. Trop. Med. Public Health 48, 20\u201332 (2017).","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"1366_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002243","volume":"7","author":"CY Huang","year":"2013","unstructured":"Huang, C. Y. et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl. Trop. Dis. 7, e2243 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1366_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/315215","volume":"181","author":"DW Vaughn","year":"2000","unstructured":"Vaughn, D. W. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2\u20139 (2000).","journal-title":"J. Infect. Dis."},{"key":"1366_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4269\/ajtmh.2003.68.191","volume":"68","author":"A Nisalak","year":"2003","unstructured":"Nisalak, A. et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am. J. Trop. Med. Hyg. 68, 191\u2013202 (2003).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000617","volume":"4","author":"JR Fried","year":"2010","unstructured":"Fried, J. R. et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl. Trop. Dis. 4, e617 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1366_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/MMBR.00009-15","volume":"79","author":"SB Halstead","year":"2015","unstructured":"Halstead, S. B. & Cohen, S. N. Dengue hemorrhagic fever at 60 years: early evolution of concepts of causation and treatment. Microbiol. Mol. Biol. Rev. 79, 281\u2013291 (2015).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"1366_CR41","doi-asserted-by":"publisher","first-page":"e0154760","DOI":"10.1371\/journal.pone.0154760","volume":"11","author":"KM Soo","year":"2016","unstructured":"Soo, K. M., Khalid, B., Ching, S. M. & Chee, H. Y. Meta-analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections. PLoS ONE 11, e0154760 (2016).","journal-title":"PLoS ONE"},{"key":"1366_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45816-6","volume":"9","author":"R Aguas","year":"2019","unstructured":"Aguas, R., Dorigatti, I., Coudeville, L., Luxemburger, C. & Ferguson, N. M. Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam. Sci. Rep. 9, 9395 (2019).","journal-title":"Sci. Rep."},{"key":"1366_CR43","doi-asserted-by":"publisher","first-page":"e0012811","DOI":"10.1371\/journal.pntd.0012811","volume":"19","author":"F Narvaez","year":"2025","unstructured":"Narvaez, F. et al. Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua. PLoS Negl. Trop. Dis. 19, e0012811 (2025).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1366_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fcimb.2017.00317","volume":"7","author":"C Guo","year":"2017","unstructured":"Guo, C. et al. Global epidemiology of dengue outbreaks in 1990\u20132015: a systematic review and meta-analysis. Front. Cell. Infect. Microbiol. 7, 317 (2017).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1366_CR45","unstructured":"Tricou, V., Moss, K. J., Pang, H., Roubinis, N. & Rauscher, M. Safety of Takeda\u2019s tetravalent dengue vaccine candidate (TAK-003) in participants with detectable vaccine viremia: combined results from the TAK-003 Clinical Development Program. Presented at 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). (Copenhagen, Denmark, 2024)."},{"key":"1366_CR46","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","volume":"74","author":"S Butrapet","year":"2000","unstructured":"Butrapet, S. et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2019 noncoding region and nonstructural proteins 1 and 3. J. Virol. 74, 3011\u20133019 (2000).","journal-title":"J. Virol."},{"key":"1366_CR47","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","volume":"33","author":"JE Osorio","year":"2015","unstructured":"Osorio, J. E., Partidos, C. D., Wallace, D. & Stinchcomb, D. T. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 33, 7112\u20137120 (2015).","journal-title":"Vaccine"},{"key":"1366_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2005.06.019","volume":"131","author":"S Butrapet","year":"2006","unstructured":"Butrapet, S., Kinney, R. M. & Huang, C. Y. Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J. Virol. Methods 131, 1\u20139 (2006).","journal-title":"J. Virol. Methods"},{"key":"1366_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/vbz.2010.0150","volume":"11","author":"AC Brault","year":"2011","unstructured":"Brault, A. C. et al. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in. Vector Borne Zoonotic Dis. 11, 683\u2013689 (2011).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"1366_CR50","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.4269\/ajtmh.17-0185","volume":"97","author":"EA Dietrich","year":"2017","unstructured":"Dietrich, E. A., Ong, Y. T., Stovall, J. L., Dean, H. & Huang, C. Y. Limited transmission potential of Takeda\u2019s tetravalent dengue vaccine candidate by Aedes albopictus. Am. J. Trop. Med. Hyg. 97, 1423\u20131427 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR51","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4269\/ajtmh.1994.51.864","volume":"51","author":"MM Khin","year":"1994","unstructured":"Khin, M. M., Jirakanjanakit, N., Yoksan, S. & Bhamarapravati, N. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in. Am. J. Trop. Med. Hyg. 51, 864\u2013869 (1994).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR52","doi-asserted-by":"publisher","first-page":"eadh3067","DOI":"10.1126\/scitranslmed.adh3067","volume":"15","author":"EE Ooi","year":"2023","unstructured":"Ooi, E. E. & Kalimuddin, S. Insights into dengue immunity from vaccine trials. Sci. Transl. Med. 15, eadh3067 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1366_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"1366_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1128\/MMBR.00024-15","volume":"80","author":"LA VanBlargan","year":"2016","unstructured":"VanBlargan, L. A., Goo, L. & Pierson, T. C. Deconstructing the antiviral neutralizing-antibody response: implications for vaccine development and immunity. Microbiol. Mol. Biol. Rev. 80, 989\u20131010 (2016).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"1366_CR55","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","volume":"7","author":"PR Beatty","year":"2015","unstructured":"Beatty, P. R. et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci. Transl. Med. 7, 304ra141 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1366_CR56","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/infdis\/jiz081","volume":"221","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 221, 867\u2013877 (2020).","journal-title":"J. Infect. Dis."},{"key":"1366_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3151","volume":"14","author":"AG Dias Jr.","year":"2022","unstructured":"Dias, A. G. Jr. et al. Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Sci. Transl. Med. 14, eabm3151 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1366_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","volume":"14","author":"B Guy","year":"2016","unstructured":"Guy, B. & Jackson, N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14, 45\u201354 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"1366_CR59","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4269\/ajtmh.16-0222","volume":"95","author":"SB Halstead","year":"2016","unstructured":"Halstead, S. B. Licensed dengue vaccine: public health conundrum and scientific challenge. Am. J. Trop. Med. Hyg. 95, 741\u2013745 (2016).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1366_CR60","doi-asserted-by":"publisher","first-page":"715136","DOI":"10.3389\/fimmu.2021.715136","volume":"12","author":"JR Pinheiro","year":"2021","unstructured":"Pinheiro, J. R. et al. Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines. Front. Immunol. 12, 715136 (2021).","journal-title":"Front. Immunol."},{"key":"1366_CR61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/v14020242","volume":"14","author":"M Mapalagamage","year":"2022","unstructured":"Mapalagamage, M., Weiskopf, D., Sette, A. & De Silva, A. D. Current understanding of the role of T cells in Chikungunya, dengue and Zika infections. Viruses 14, 242 (2022).","journal-title":"Viruses"},{"key":"1366_CR62","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1016\/j.vaccine.2017.07.045","volume":"35","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. & Harris, E. Participants in the Summit on Dengue Immune Correlates of Protection. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine 35, 4659\u20134669 (2017).","journal-title":"Vaccine"},{"key":"1366_CR63","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","volume":"14","author":"JE Osorio","year":"2014","unstructured":"Osorio, J. E. et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14, 830\u2013838 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"1366_CR64","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","volume":"212","author":"SL George","year":"2015","unstructured":"George, S. L. et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J. Infect. Dis. 212, 1032\u20131041 (2015).","journal-title":"J. Infect. Dis."},{"key":"1366_CR65","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","volume":"33","author":"R Rupp","year":"2015","unstructured":"Rupp, R. et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine 33, 6351\u20136359 (2015).","journal-title":"Vaccine"},{"key":"1366_CR66","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","volume":"36","author":"LA Jackson","year":"2018","unstructured":"Jackson, L. A. et al. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Vaccine 36, 3976\u20133983 (2018).","journal-title":"Vaccine"},{"key":"1366_CR67","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","volume":"38","author":"V Tricou","year":"2020","unstructured":"Tricou, V. et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial. Vaccine 38, 1513\u20131519 (2020).","journal-title":"Vaccine"},{"key":"1366_CR68","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","volume":"395","author":"V Tricou","year":"2020","unstructured":"Tricou, V. et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet 395, 1434\u20131443 (2020).","journal-title":"Lancet"},{"key":"1366_CR69","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","volume":"217","author":"JA Swanstrom","year":"2018","unstructured":"Swanstrom, J. A. et al. Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 217, 1932\u20131941 (2018).","journal-title":"J. Infect. Dis."},{"key":"1366_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009258","volume":"15","author":"LJ White","year":"2021","unstructured":"White, L. J. et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLoS Negl. Trop. Dis. 15, e0009258 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1366_CR71","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/infdis\/jiac272","volume":"226","author":"CR DeMaso","year":"2022","unstructured":"DeMaso, C. R. et al. Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine. J. Infect. Dis. 226, 1959\u20131963 (2022).","journal-title":"J. Infect. Dis."},{"key":"1366_CR72","doi-asserted-by":"publisher","first-page":"840104","DOI":"10.3389\/fimmu.2022.840104","volume":"13","author":"J Hou","year":"2022","unstructured":"Hou, J., Ye, W. & Chen, J. Current development and challenges of tetravalent live-attenuated dengue vaccines. Front. Immunol. 13, 840104 (2022).","journal-title":"Front. Immunol."},{"key":"1366_CR73","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","volume":"20","author":"EG Kallas","year":"2020","unstructured":"Kallas, E. G. et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect. Dis. 20, 839\u2013850 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1366_CR74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","volume":"390","author":"EG Kall\u00e1s","year":"2024","unstructured":"Kall\u00e1s, E. G. et al. Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults. N. Engl. J. Med. 390, 397\u2013408 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1366_CR75","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/infdis\/jiv258","volume":"212","author":"H Chu","year":"2015","unstructured":"Chu, H., George, S. L., Stinchcomb, D. T., Osorio, J. E. & Partidos, C. D. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 212, 1618\u20131628 (2015).","journal-title":"J. Infect. Dis."},{"key":"1366_CR76","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","volume":"10","author":"AT Waickman","year":"2019","unstructured":"Waickman, A. T. et al. Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Front. Immunol. 10, 1778 (2019).","journal-title":"Front. Immunol."},{"key":"1366_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11634-7","volume":"10","author":"AT Waickman","year":"2019","unstructured":"Waickman, A. T. et al. Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling. Nat. Commun. 10, 3666 (2019).","journal-title":"Nat. Commun."},{"key":"1366_CR78","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.vaccine.2022.01.016","volume":"40","author":"V Tricou","year":"2022","unstructured":"Tricou, V. et al. Characterization of the cell-mediated immune response to Takeda\u2019s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. Vaccine 40, 1143\u20131151 (2022).","journal-title":"Vaccine"},{"key":"1366_CR79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/infdis\/jiaa346","volume":"223","author":"D Michlmayr","year":"2021","unstructured":"Michlmayr, D. et al. Characterization of the type-specific and cross-reactive B-cell responses elicited by a live-attenuated tetravalent dengue vaccine. J. Infect. Dis. 223, 247\u2013257 (2021).","journal-title":"J. Infect. Dis."},{"key":"1366_CR80","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/infdis\/jiac476","volume":"227","author":"EJM Nascimento","year":"2023","unstructured":"Nascimento, E. J. M. et al. Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system. J. Infect. Dis. 227, 1282\u20131292 (2023).","journal-title":"J. Infect. Dis."},{"key":"1366_CR81","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou, V. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 12, e257\u2013e270 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1366_CR82","doi-asserted-by":"publisher","first-page":"e1214","DOI":"10.1093\/infdis\/jiae222","volume":"230","author":"C Sirivichayakul","year":"2024","unstructured":"Sirivichayakul, C. et al. Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or Yellow fever vaccination. J Infect. Dis. 230, e1214\u2013e1225 (2024).","journal-title":"J Infect. Dis."},{"key":"1366_CR83","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","volume":"17","author":"X S\u00e1ez-Llorens","year":"2017","unstructured":"S\u00e1ez-Llorens, X. et al. Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect. Dis. 17, 615\u2013625 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"1366_CR84","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","volume":"18","author":"X S\u00e1ez-Llorens","year":"2018","unstructured":"S\u00e1ez-Llorens, X. et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect. Dis. 18, 162\u2013170 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1366_CR85","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. N. Engl. J. Med. 381, 2009\u20132019 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1366_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115790119","volume":"119","author":"AT Huang","year":"2022","unstructured":"Huang, A. T. et al. Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand. Proc. Natl. Acad. Sci. USA 119, e2115790119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1366_CR87","unstructured":"Pfaar, H., Escudero, I., Roubinis, N., Thakrar, S. & Tuboi, S. Febrile surveillance in a multi-country phase III randomized trial evaluating the efficacy and safety of a tetravalent live-attenuated dengue vaccine in children and adolescents. Presented at SLIPE 2023 - XX Latin American Congress of Pediatric Infectious Diseases. (San Jos\u00e9, CostaRica, 2023)."},{"key":"1366_CR88","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: conclusions and recommendations. Wkly. Epidemiol. Rec. 98, 599\u2013620 (2023)."}],"updated-by":[{"DOI":"10.1038\/s41541-026-01471-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01366-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:02:08Z","timestamp":1778191328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01366-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01366-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41541-026-01471-3","URL":"https:\/\/doi.org\/10.1038\/s41541-026-01471-3","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. is a full-time employee of Takeda, holds Takeda stock, and is an inventor on the patent application with application number PCT\/US2022\/022822. I.E., S.B., and J.W. are employees of Takeda Vaccines and hold Takeda stock. D.W. is an employee of Takeda Vaccines, holds Takeda stock, and is an inventor on the patent applications WO 2017\/179017, WO 2020\/051334 and WO 2021\/034349. D.G., E.P., and G.P. were Takeda employees at the time of manuscript development.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}